CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial

CONCLUSIONS: The KENDO trial, although closed prematurely, adds further evidence supporting CDK4/6i + ET use in aggressive HR+/HER2-negative MBC instead of chemotherapy. PAM50 IS, genomic, and immunological features are promising biomarkers to personalize therapeutic choices.PMID:38175669 | DOI:10.1093/oncolo/oyad337

Source: The Oncologist - January 4, 2024 Category: Cancer & Oncology Authors: Francesco Schettini Michela Palleschi Francesca Mannozzi Fara Bras ó-Maristany Lorenzo Cecconetto Patricia Galv án Marita Mariotti Alessia Ferrari Emanuela Scarpi Anna Miserocchi Oriana Nanni Esther Sanfeliu Aleix Prat Andrea Rocca Ugo De Giorgi Source Type: research